title: Radioprotectants: current status and new directions.
abstract: The ability to prevent radiotherapy-induced toxicity without affecting antitumor efficacy has the potential to enhance the therapeutic benefit for cancer patients without increasing their risk of serious adverse effects. Among the currently available cytoprotective agents capable of protecting normal tissue against damage caused by either chemo- or radiotherapy, only amifostine has been shown in clinical trials to reduce radiation-induced toxicity. Most notably, it reduces the incidence of xerostomia, which is a clinically significant long-term toxicity arising in patients undergoing irradiation of head and neck cancers. In vitro studies with the active metabolite of amifostine (WR-1065) have shown it to prevent both radiation-induced cell death and radiation-induced mutagenesis. The potential of this agent to prevent secondary tumors, as well as other radiation-induced toxicities is now the focus of ongoing research. Among other novel approaches to radioprotection being explored are methods to increase levels of the antioxidant mitochondrial enzyme manganese superoxide dismutase (MnSOD). In addition, the use of epoetin alfa, alone or in combination with cytoprotectants (e.g., amifostine), to treat radiation-induced anemia is also being investigated. The objective of developing newer cytoprotective therapies is to improve the therapeutic ratio by reducing the acute and chronic toxicities associated with more intensive and more effective anticancer therapies.
authors.affiliation: Department of Radiation and Cellular Oncology, The University of Chicago, Chicago, Ill. 60637, USA. dgrdina@rover.uchicago.edu
authors.forename: David J
authors.initials: DJ
authors.lastname: Grdina
authors.forename: Jeffrey S
authors.initials: JS
authors.lastname: Murley
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Kataoka
mesh_terms: D000171:Acrolein / Q000009:adverse effects; D004999:Amifostine / Q000494:pharmacology*; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004307:Dose-Response Relationship, Radiation; D006321:Heart / Q000187:drug effects; D006801:Humans; D015080:Mesna / Q000494:pharmacology; D016296:Mutagenesis / Q000187:drug effects*; D010078:Oxazines / Q000009:adverse effects; D011837:Radiation-Protective Agents / Q000494:pharmacology*; D011878:Radiotherapy / Q000009:adverse effects*; D011929:Razoxane / Q000494:pharmacology
chemical_list: D000903:Antibiotics, Antineoplastic; D018906:Antineoplastic Agents, Alkylating; D010078:Oxazines; D011837:Radiation-Protective Agents; D011929:Razoxane; D000171:Acrolein; D004999:Amifostine; D015080:Mesna